Two recent signs underscore the inexorable mainstreaming of psilocybin fungi, aka “magic mushrooms.” One is a recent poll of voters in Colorado (more on that below). The other involves my wife. Let’s start with her.
My wife Carole is a voracious consumer of a wide variety of media, making her a handy barometer for the cultural zeitgeist. She pays attention to certain TV shows, magazines, and sections of the newspaper that I tend to ignore but which reflect popular trends that can affect the investment world.
Just yesterday, she pointed out to me an article on magic mushrooms in the latest issue of Marie Claire, a glossy hard-copy women’s fashion magazine that’s a fixture on our coffee table. She knows I write Marijuana Investing Daily and she figured I would find the article of interest. How right she was.
Here’s an excerpt of the magazine article, titled How to Feel Better Now, in the “Beauty” section of the publication:
“The exploration of psychedelic drugs (like psilocybin, LSD, and, more recently, MDMA) for medicinal versus recreational purposes is many decades old. In recent years, though, psychedelics have been experiencing a bit of a renaissance…Now, the drugs are further seeping into the mainstream via microdosing.
Defined as an extremely low, sub-hallucinogenic dose of a substance, usually 1/10 to 1/20 of a typical recreational dose, a microdose might slightly alter perception yet not impair one’s ability to function…microdosing is a way of tinkering with the serotonin system…and we know that augmenting it in a chronic way can help with depression.”
The article goes on to relate the personal experiences of young “power” women who microdose magic mushrooms to be more effective at home, at work and (you guessed it) in the bedroom.
And there you have it, folks. Compelling evidence that psychedelics are entering mainstream society, which spells a big payday for early investors.
Psychedelic fungi are experiencing a bonanza that goes beyond their recreational or health benefits. They’re entering the world of soccer moms, yoga pants and lattes. Perhaps one day, next to the perfume case at Macy’s, we’ll see bottles of designer psilocybin.
The time to invest in these nascent “megatrends” is ahead of the curve, before they become entrenched, pervasive and obvious. Proactive investors get rewarded, whereas the Johnny-come-latelys miss out.
That’s why you should jump aboard the magic mushroom express right away, before the guests on Oprah Winfrey’s podcast start raving about the beauty secrets of psychedelic fungi. By then, the opportunity to reap massive investment gains will have passed.
Magic mushrooms contain a naturally occurring psychoactive and hallucinogenic compound called psilocybin. This compound creates altered perceptions of reality, causing users to see, hear, and feel sensations that don’t really exist outside of the mind’s eye.
But magic mushrooms aren’t just for getting high and wandering in the desert like Jim Morrison. Scientific research shows they can alleviate physical pain, depression, anxiety, chronic headaches, PTSD, and a host of other ailments. Magic mushrooms are on track to play vital roles in the future of therapy, in medicine and psychiatry.
The movement to decriminalize psychedelics is gathering momentum around the country, reminiscent of the early days of marijuana decriminalization. Psychedelics reform bills have been introduced in several state legislatures and activists are lining up ballot initiatives.
High times in the Mile High City…
Recent case in point: Half of likely Colorado voters would support a statewide measure to decriminalize possession of psilocybin mushrooms and establish a system of legal cultivation and sales of the psychedelic fungi, according to a new poll. The poll results are motivating pro-mushroom activists to launch a campaign to put the policy change on the ballot in 2022.
About one year after Denver became the first city in the U.S. to decriminalize possession of magic mushrooms, the survey shows that voters are willing to legalize the fungi to allow its use as a treatment for a variety of mental health issues.
Here’s the language of a hypothetical ballot initiative that 500 likely voters in Colorado were asked to evaluate:
“Shall there be a change to the Colorado Revised Statutes concerning psilocybin mushrooms, decriminalizing sale and possession for personal use of psilocybin mushrooms by persons 21 and older; allowing qualified mental health providers to authorize access to psilocybin mushrooms for people with depression, anxiety and other qualifying conditions including terminal illnesses; enacting necessary fees and licenses for qualified medical facilities run by qualified owners; requiring the State to license and regulate the cultivation, processing and sales of psilocybin mushrooms as well as impose penalties for violations of such regulations; and requiring that a review panel appointed by the Governor report annually on the implementation of this revised statute?”
Fifty percent said they would back such a measure, including 29% who said they were a “strong yes.” The poll was conducted by RBI Strategies & Research from March 17-19 (see chart).
The poll also asked respondents about alternative language. A majority of likely voters (54%) said they would favor a proposal to decriminalize and legalize “certain natural remedies including psilocybin.”
Entrepreneurial businesses are popping up to serve the growing demand for magic mushrooms. Cannabis already is Big Business and as such, the major pot players are likely to co-opt the psychedelics movement through internal investments as well as mergers and acquisitions.
Our analysts have been researching the exciting investment opportunities in magic mushrooms. In fact, we’ve pinpointed one company that’s poised to dominate this emerging industry and reap the lion’s share of the investment spoils. Click here for details.
Questions or comments about the revolution in psychedelics? Drop me a line: firstname.lastname@example.org
John Persinos is the editor-in-chief of Marijuana Investing Daily.